Ranbaxy and Pfenex tie up for biosimilar protein
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories and Pfenex have entered into an agreement under which the Indian firm will develop an undisclosed biosimilar therapeutic produced using the Pfenex Expression Technology, a Pseudomonas fluorescens-based recombinant protein expression system.